William Blair Forecasts Weaker Earnings for Sera Prognostics

Sera Prognostics, Inc. (NASDAQ:SERA - Free Report) - Investment analysts at William Blair cut their Q3 2025 earnings per share estimates for shares of Sera Prognostics in a research note issued on Monday, February 3rd. William Blair analyst A. Brackmann now anticipates that the company will post earnings of ($0.24) per share for the quarter, down from their prior estimate of ($0.23). The consensus estimate for Sera Prognostics' current full-year earnings is ($0.96) per share. William Blair also issued estimates for Sera Prognostics' Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($0.98) EPS.

Sera Prognostics Trading Down 3.6 %

NASDAQ:SERA traded down $0.17 during trading hours on Wednesday, hitting $4.54. The stock had a trading volume of 91,406 shares, compared to its average volume of 99,464. The business has a 50 day simple moving average of $7.19 and a two-hundred day simple moving average of $7.26. Sera Prognostics has a 1-year low of $4.50 and a 1-year high of $12.35. The company has a market cap of $153.32 million, a PE ratio of -4.59 and a beta of 0.81.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.02). The company had revenue of $0.03 million for the quarter, compared to analysts' expectations of $0.09 million. During the same period last year, the business posted ($0.23) earnings per share.

Institutional Trading of Sera Prognostics

Several hedge funds have recently made changes to their positions in SERA. Quest Partners LLC grew its position in shares of Sera Prognostics by 533.5% during the third quarter. Quest Partners LLC now owns 6,430 shares of the company's stock worth $50,000 after acquiring an additional 5,415 shares during the last quarter. The Manufacturers Life Insurance Company bought a new position in Sera Prognostics in the 2nd quarter worth approximately $68,000. SG Americas Securities LLC bought a new stake in Sera Prognostics during the 3rd quarter valued at $78,000. Prime Capital Investment Advisors LLC acquired a new position in Sera Prognostics during the 3rd quarter worth $104,000. Finally, Jane Street Group LLC grew its stake in shares of Sera Prognostics by 24.8% in the third quarter. Jane Street Group LLC now owns 14,225 shares of the company's stock worth $111,000 after purchasing an additional 2,826 shares in the last quarter. Institutional investors own 54.64% of the company's stock.

Insider Activity at Sera Prognostics

In related news, insider Paul Kearney sold 4,078 shares of the business's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $7.32, for a total value of $29,850.96. Following the completion of the sale, the insider now directly owns 176,889 shares of the company's stock, valued at $1,294,827.48. The trade was a 2.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Zhenya Lindgardt sold 12,075 shares of Sera Prognostics stock in a transaction on Monday, November 11th. The stock was sold at an average price of $7.32, for a total transaction of $88,389.00. Following the completion of the transaction, the chief executive officer now directly owns 819,758 shares of the company's stock, valued at approximately $6,000,628.56. This represents a 1.45 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 93,215 shares of company stock valued at $666,835. Corporate insiders own 15.80% of the company's stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.